XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). XL092 is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing.

Trial Details

NCT ID
NCT06959641
Phase
PHASE2
Sponsor
Jochen Lorch
Status
RECRUITING
Cancer Type
Papillary Thyroid Cancer
Interventions
  • Biospecimen Collection
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Survey Administration
  • X-Ray Imaging
  • Zanzalintinib
Locations (sample)
  • Torrance, California, United States|33.83585,-118.34063
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • 1.1 Patients must have a histologically confirmed locally advanced or metastatic, radioactive iodine (RAI) refractory, differentiated thyroid cance…
  • 1.2 Patients must have measurable disease according to RECIST v1.1 (see Appendix B and Section 2).
  • 1.3 Patients must be age ≥ 18 years.
  • 1.4 Patients must exhibit an ECOG Performance Score of ≤ 2 (see Appendix C for ECOG Performance Status Scale).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Papillary Thyroid Cancer Trials on Trialify →